Guillaume Lassailly: The Role of MASH, Fibrosis in Bariatric Surgery Survival
The study author discusses the impact of findings showing MASH resolution without worsening fibrosis is a surrogate endpoint for 15-year bariatric surgery survival.
Read More
Rohit Loomba, MD, MHSc: Future Treatments and Strategies in MASH
Loomba discusses how practices like his own are adapting to the new nomenclature in metabolic-associated liver disease.
Serum Bile Acid Independently Predicts Liver Survival in Alagille Syndrome with Neonatal Cholestasis
A new study from the GALA cohort shows serum bile acid's association with clinical outcomes is relevant in the context of IBAT inhibitor therapy.
Arun Sanyal, MD: Retatrutide and GLP-1 Agonists in MASLD
Sanyal discusses the makeup of retatrutide and its potential for patients with fatty liver disease and comorbid metabolic conditions.
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
Pooled data from The Liver Meeting showed odevixibat sustains itch and serum bile acid benefits in patients with Alagille syndrome. An investigators shares what he wants to learn next.
Pegozafermin Significantly Improves Fibrosis in Patients with MASH
Post hoc phase 2b analyses suggest peogzafermin may benefit severe fibrosis regardless of MASH patients' cirrhosis status.
Retatrutide Clears Fatty Liver Disease in >85% of Patients with Obesity
Retatrutide, an investigational triple-agonist therapy, may help resolve liver fat prior to progression to severe disease.
Odevixibat Maintains Alagille Syndrome Pruritus, Bile Acid Reductions at 36 Weeks
New pooled phase 3 and extension trial data show odevixibat continues to improve disease management and itch reduction in children with Alagille syndrome.
Resolving MASH Without Worsening Fibrosis Improves Post-Bariatric Surgery Survival
Investigators observe significantly greater 15-year survival rates after bariatric surgery among patients who achieve MASH resolution versus those who do not.
VTP-300 Plus Nivolumab Lowers HBsAG, Shows Potential for HBV Cure Regimen
Interim data presented at The Liver Meeting highlight the novel antigen-specific immunotherapy's potential in resolving hepatitis B.
Can the US Replicate India's Hepatitis C Eradication Model?
Madhumita Premkumar, MD, discusses a nationwide, cost-efficient eradication strategy she believes could benefit Americans' efforts to curb HCV.
Resmetirom Significantly Reduces LDL-C, Restore Thyroid Hormones in NASH with Fibrosis
New analyses from the phase 3 MAESTRO-NASH support the oral daily drug's benefit for cardiovascular and hormonal outcomes over 1 year.
Women at 50% Greater Risk Progressing from Alcoholic Hepatitis to Cirrhosis than Men
Findings from The Liver Meeting show the impact of acute alcoholic hepatitis on progression to severe disease and risk of death among younger populations.
Jennifer Flemming, MD, FRCPC: Why Are More Women Developing Alcohol-Associated Liver Disease?
As more cases continue to disproportionately affect US women, an expert explains the biologic, sociocultural and clinical factors impacting the climb.
Prioritizing Gut Health, Bile Acid Research in Liver Disease Care
A trio of investigators discuss how research into bile acid interplay with the gut may lead to breakthroughs in treating conditions like NAFLD and NASH.
Ricky Safer: Working to Streamline Primary Sclerosing Cholangitis Diagnoses
The founder of PSC Partners Seeking a Cure discusses how screening and treatment for the rare disease has evolved since her diagnosis 20 years ago.
Bile Acids in Gut, Brain and Liver Health: What Do We Know?
A trio of scientists discuss the inception of a daylong Liver Meeting symposium around a little-understood subject in hepatic disease.
Infliximab Biosimilars Not Linked to Worsened Infection Risk
An analysis of national Canadian data suggest patients receiving either originator or biosimilar infliximab are at a similar risk of the common adverse event.
Trastuzumab Biosimilar Use Significantly Increasing in the US
Analysis shows the rate of use with the originator biologic has decreased from 90% in 2016, to 19% in 2021.
Switching with Adalimumab Biosimilar Maintains Benefit for Plaque Psoriasis
Trial data support multiple switching between biosimilar and reference product over a 48-week course for the treatment of psoriasis.
The Four-Time Stage IV Lung Cancer Patient
For Lung Cancer Awareness Month, Lungcast speaks with Christy Fischer, a patient who's spent the last 17 years fighting late-stage cancer.
Switchback from Biosimilar to Biologic Rare Among Veteran Patients
Very few patients switch off a biosimilar due to adverse effects, according to a new study.
FDA Warns Against Glucose Control Product Containing Metformin, Glyburide
Consumers should avoid Dr. Ergin’s SugarMD Advanced Glucose Support due to an increased risk of adverse events including hypoglycemia.
Semaglutide Does Not Worsen Diabetic Retinopathy Status
Despite recommendations to consult with ophthalmologists prior to initiating semaglutide, the cardiometabolic drug was not found to be linked to worsened DR outcomes.
SGLT-2 Inhibitors Reduce Glaucoma Risk in Type 2 Diabetes Patients
New AAO 2023 data suggests drugs like dapagliflozin and empagliflozin may provide greater protection against glaucoma than GLP-1 agonists or DDP-4 inhibitors.
Switching to Faricimab Improves nAMD Dryness, Reduces Treatment Burden
New data from the Cleveland Clinic Cole Eye Institute showed patients not responding to anti-VEGF inhibitors could improve clinical and regimen parameters with short-term faricimab.
FDA Approves Secukinumab for Hidradenitis Suppurativa
Secukinumab (Cosentyx) becomes the first IL-17A inhibitor, as well as the first drug since 2015, approved to treat adults with moderate to severe HS.
Andreas Kremer, MD, PhD, MHBA: Seladelpar for the Treatment of PBC
Kremer discusses new ad hoc findings from the phase 3 ENHANCE trial showing seladelpar's unique effect on pruritus in patients with PBC.
Etrasimod Significantly Benefits Ulcerative Colitis Regardless of Corticosteroids
New data from ACG 2023 shows etrasimod-treated patients were able to achieve UC remission, with or without concomitant steroid treatment at baseline.
Guselkumab Benefits Ulcerative Colitis Regardless of Patient Treatment History
New QUASAR analysis shows patients with intolerance or failed response to advanced therapies nonetheless achieved benefit with guselkumab.